Physician profile
Travis Michael Cox
NPI 1982090981
$7,067.80
in general payments reported to CMS, 2019-2025
46 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $716 · 2021: $213 · 2022: $939 · 2023: $513 · 2024: $1,792 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,075 · Education: $67.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,075.34 |
| Education | $67.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $784.54 | 2020-2025 | Erleada, Tecvayli, Rybrevant |
| Amgen INC. | $494.44 | 2019-2024 | Vectibix |
| Incyte Corporation | $454.42 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Astrazeneca Pharmaceuticals LP | $408.69 | 2022-2025 | Calquence, Lynparza, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $404.38 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Astellas Pharma US INC | $393.29 | 2020-2025 | Padcev, Xospata |
| Regeneron Healthcare Solutions, INC. | $309.00 | 2019-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $287.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $280.32 | 2022-2025 | |
| Glaxosmithkline, LLC. | $267.99 | 2021-2025 | Ojjaara, Jemperli |
| Pfizer INC. | $266.08 | 2022-2025 | |
| Lilly USA, LLC | $233.21 | 2019-2025 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $213.31 | 2022-2025 | |
| Celgene Corporation | $204.54 | 2019-2025 | Opdivo, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $202.10 | 2023-2025 | Vanflyta, Enhertu, Injectafer |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $152.67 | 2024-2025 | Fruzaqla, Ninlaro, Iclusig |
| Merck Sharp & Dohme LLC | $149.23 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Array Biopharma INC | $141.41 | 2022-2025 | Braftovi, Lorbrena, Xalkori |
| Rigel Pharmaceuticals, INC. | $141.25 | 2020-2021 | |
| Kite Pharma, INC. | $136.53 | 2020-2025 | Yescarta |
| Lexicon Pharmaceuticals, INC. | $124.94 | 2019 | |
| Penumbra, INC. | $106.77 | 2024 | Indigo System |
| Genentech USA, INC. | $103.20 | 2019-2024 | Tecentriq, Polivy |
| Taiho Oncology, INC. | $84.65 | 2022-2025 | |
| Sobi, INC | $76.87 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $66.25 | 2022-2025 | Fotivda |
| Abbvie INC. | $56.75 | 2025 | |
| Gilead Sciences, INC. | $56.56 | 2024-2025 | Trodelvy |
| Eisai INC. | $43.88 | 2025 | |
| Alexion Pharmaceuticals, INC. | $43.79 | 2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $37.93 | 2024 | |
| Springworks Therapeutics, INC. | $34.32 | 2025 | Gomekli |
| Stemline Therapeutics INC. | $33.15 | 2024-2025 | Orserdu |
| Legend Biotech USA INC. | $31.02 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $28.55 | 2022-2025 | Xpovio |
| Beigene USA, INC. | $27.99 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $24.09 | 2025 | Orgovyx |
| Servier Pharmaceuticals LLC | $22.97 | 2024 | |
| Mirati Therapeutics, INC. | $21.30 | 2023 | Krazati |
| Emd Serono, INC. | $20.29 | 2024 | |
| Puma Biotechnology, INC. | $19.26 | 2024 | |
| Myriad Genetic Laboratories, INC. | $17.09 | 2022 | |
| Tempus Ai, INC | $16.80 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $16.59 | 2024 | Onivyde, Somatuline Depot |
| Agios Pharmaceuticals, INC. | $14.10 | 2023 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.